|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In breast cancer (BC), elevated levels of urokinase-type plasminogen activator (uPA) in tumor tissue have been confirmed as a strong prognostic factor in level-of-evidence-1 studies.
|
30783124 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator (uPA) is a diagnostic marker for breast and prostate cancers recommended by American Society for Clinical Oncology and German Breast Cancer Society.
|
30707839 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Fluid shear stress stimulates breast cancer cells to display invasive and chemoresistant phenotypes while upregulating PLAU in a 3D bioreactor.
|
31317530 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Determination of uPA and PAI-1 concentrations in the breast cancer tissue extracts was performed using FEMTELLE® uPA/PAI-1 ELISA.
|
30646864 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
|
29107218 |
2018 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, uPAR PET imaging using a <sup>68</sup>Ga-labeled version of the uPAR-targeting peptide (AE105) was investigated in a group of patients with BC, PC, and UBC.
|
27609788 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Additionally, SDC1 is positively associated with PLAU and might act as a potential prognostic indicator for breast cancer.
|
29340066 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator (uPA) has been validated as a predictive or prognostic biomarker protein, and mesupron is considered the first-in-class anticancer agent to inhibit uPA activity in human breast cancer.
|
28560500 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Genetic deficiency of uPA leads to a significant reduction in metastases in the murine transgenic MMTV-PyMT breast cancer model, demonstrating a causal role for uPA in cancer dissemination.
|
26040548 |
2015 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Urokinase type plasminogen activator (uPA) is a serine protease that is involved in cancer progression, especially invasion and metastasis of breast cancer.
|
25377085 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although uPA can be transiently upregulated by diverse extracellular stimuli, sustained, but not transiently upregulated uPA expression contributes to breast cancer invasion/metastasis.
|
22986534 |
2013 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review focuses on uPA system, summarizes their biological effects, highlights the molecular mechanism and pathway, and discusses the role of uPA system in the prevention and treatment of human breast cancers.
|
23201006 |
2013 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
The transition in uPAR signaling from uPA-dependent and transient to autonomous and sustained is reminiscent of the transformation in ErbB2/HER2 signaling observed when this gene is amplified in breast cancer. uPAR over-expression may provide a pathway for escape of breast cancer cells from ERα-targeting therapeutics.
|
22617030 |
2012 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, we characterized adipocytes from breast and omental tissues for PAI-1 and uPA, and the influence of adipocytes on breast cancer cell motility.
|
22445926 |
2012 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
By using microarray profiling of breast cancer cell lines that had undergone siRNA-mediated abrogation of Notch signaling we uncovered a link between activated Notch signaling and uPA expression.
|
21199807 |
2011 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Using an ARE-gene microarray, novel targets of TTP regulation were identified, namely, urokinase plasminogen activator (uPA), uPA receptor and matrix metalloproteinase-1, all known to have prominent roles in breast cancer invasion and metastasis.
|
20498646 |
2010 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
For using uPA and PAI-1 levels as prognostic and predictive factors in breast cancer the quantity of tumor stroma in the tumor tissue specimen is not relevant for assessment patients outcome.
|
19082473 |
2009 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study describes the synthesis and preliminary biologic evaluation of an (111)In-labeled peptide antagonist of the urokinase-type plasminogen activator receptor (uPAR) as a potential probe for assessing metastatic potential of human breast cancer in vivo.
|
19354275 |
2009 |
|
Malignant neoplasm of breast
|
0.300 |
Therapeutic
|
disease |
RGD |
Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
|
19500378 |
2009 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
When using uPA- and PAI-1 levels as prognostic and predictive factors in breast cancer the quantity of tumor stroma in the tumor tissue specimen is not relevant for the assessment of the patients' outcome.
|
19475533 |
2009 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
|
19701247 |
2009 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Highly sensitive quantitative real-time PCR (QPCR) assays, based on the LightCycler technology, were established to quantify uPA and PAI-1 mRNA expression in breast cancer cell lines as well as in tumor tissue of breast cancer patients. mRNA concentrations were normalized to the expression level of the housekeeping gene h-G6PDH.
|
18204793 |
2008 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
|
16963728 |
2006 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
As Ets2 binding sites are present on the uPA promoter, Ets2 may be one of the transcription factors regulating uPA expression in human breast cancer.
|
16380248 |
2006 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, HMW-uPA and ATF induce proliferation of breast cancer cells by binding to uPAR.
|
16685447 |
2006 |